CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.12B, above the global median of $1.2B
- FinancialsAltman Z-Score 6.38: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
2.12BUSDvs all stocks (USD)
Revenue (TTM)
52.05MUSDvs all stocks (USD)
Beta
0.9680xvs all stocks
52-Week Change
-22.99%vs all stocks
Market Capitalization
2.12BUSDvs all stocks (USD)
Enterprise Value
1.60BUSDvs all stocks (USD)
Forward P/E
-6.64xvs Biotechnology peers
Price to Sales (TTM)
40.71xvs Biotechnology peers
Price to Book (MRQ)
4.08xvs Biotechnology peers
Enterprise to Revenue
30.74xvs Biotechnology peers
Enterprise to EBITDA
-5.19xvs Biotechnology peers
Gross Margin
85.08%vs Biotechnology peers
Operating Margin
-609.34%vs Biotechnology peers
Return on Assets (TTM)
-34.95%vs Biotechnology peers
Return on Equity (TTM)
-72.99%vs Biotechnology peers
Revenue (TTM)
52.05MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2430USDUpdated Sep 28, 2026Quarterly Revenue Growth
0.10%vs Biotechnology peers
Gross Profit (TTM)
-178.16MUSDvs all stocks (USD)
EBITDA (TTM)
-308.46MUSDvs all stocks (USD)
Net Income (TTM)
-301.45MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
0.12%vs Biotechnology peers
Operating Cash Flow (TTM)
-238.24MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-159.25MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
51.95MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.57MUSDFY2025 · Dec 31, 2025Gross Profit
45.38MUSDFY2025 · Dec 31, 2025Operating Income
-270.02MUSDvs all stocks (USD)
Pre-tax Income
-265.94MUSDFY2025 · Dec 31, 2025Net Income
-265.94MUSDFY2025 · Dec 31, 2025EBIT
-254.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-247.31MUSDFY2025 · Dec 31, 2025Research & Development
197.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
118.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.36MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
11.84MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.42USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.42USDFY2025 · Dec 31, 2025Basic Shares Outstanding
187.24MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
187.24MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-265.94MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-215.18MUSDFY2025 · Dec 31, 2025Free Cash Flow
-227.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
738.67MUSDFY2025 · Dec 31, 2025Interest Paid
9.03MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-265.94MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
43.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.40MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.74MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-887.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-991.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.88MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-11.88MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
541.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
219.59MSharesUpdated Sep 28, 2026Float Shares
184.76MSharesUpdated Sep 28, 2026Shares Short
29.93MSharesUpdated Sep 28, 2026Short Ratio
11.11daysvs all stocks
Short % of Shares Outstanding
16.09%vs all stocks
% Held by Insiders
0.93%vs all stocks
% Held by Institutions
95.70%vs all stocks
Total Cash (MRQ)
598.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.73USDUpdated Sep 28, 2026Total Debt (MRQ)
79.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1527xvs Biotechnology peers
Current Ratio (MRQ)
13.11xvs Biotechnology peers
Book Value per Share (MRQ)
2.37USDUpdated Sep 28, 2026Total Assets
808.06MUSDvs all stocks (USD)
Total Current Assets
782.13MUSDFY2025 · Dec 31, 2025Total Liabilities
153.75MUSDFY2025 · Dec 31, 2025Total Non-current Assets
25.93MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
102.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
50.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
737.06MUSDFY2025 · Dec 31, 2025Accounts Receivable
30.65MUSDFY2025 · Dec 31, 2025Inventory
3.56MUSDFY2025 · Dec 31, 2025Accounts Payable
4.15MUSDFY2025 · Dec 31, 2025Short-term Debt
2.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
74.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
887.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
22.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.16BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
654.31MUSDvs all stocks (USD)
52-Week Low
6.23USDUpdated Sep 28, 202652-Week High
16.44USDUpdated Sep 28, 202652-Week Change
-22.99%vs all stocks
Beta
0.9680xvs all stocks
50-Day MA
9.89USDUpdated Sep 28, 2026200-Day MA
9.81USDUpdated Sep 28, 2026Avg 10-Day Volume
2.37MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.61MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-1.40USDUpdated Sep 28, 2026Other Income / Expense
-2.44MUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 40.71Revenue Growth YoY: 0.00
Financial Health
Altman Z-Score 6.38: safe zoneNotable
Altman Z-Score: 6.38
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.12B, above the global median of $1.2BNotable
Market cap (USD): 2,119,293,126Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pell Bio-Med Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Draganfly Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Archer Aviation Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
AST SpaceMobile, Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets